Alterity Therapeutics Announced Alignment With FDA On Pivotal Phase 3 ATH434 Program In Multiple System Atrophy; FDA Agrees To Phase 3 Design Including UMSARS Part I As Primary Endpoint

Loading news article.

Alterity Therapeutics Announced Alignment With FDA On Pivotal Phase 3 ATH434 Program In Multiple System Atrophy; FDA Agrees To Phase 3 Design Including UMSARS Part I As Primary Endpoint | WAPE

Alterity Therapeutics Announced Alignment With FDA On Pivotal Phase 3 ATH434 Program In Multiple System Atrophy; FDA Agrees To Phase 3 Design Including UMSARS Part I As Primary Endpoint

Article summary

Related companies

Comments —